rAAV production cost analysis: Indication-specific cost per dose and reduction strategies.
Recombinant adeno-associated virus (rAAV) vectors underpin many approved and late-stage gene therapies, yet manufacturing costs remain a major driver of therapy price. Here, we present the first comprehensive, platform-resolved cost analysis of rAAV production across three industrially relevant suspension platforms: tr...